UroGen Pharma Announces Upcoming 2021 Conferences

Rhea-AI Summary

UroGen Pharma Ltd. (Nasdaq: URGN) announced its participation in two virtual healthcare conferences in November: the Stifel 2021 Virtual Healthcare Conference on November 17 at 9:20 a.m. ET and the Jefferies London Healthcare Conference with an on-demand Fireside Chat available starting November 18 at 3:00 a.m. ET. Webcasts for these events will be accessible via UroGen's website for 30 days. UroGen focuses on developing novel treatments for urothelial and specialty cancers, leveraging its RTGel™ technology for enhanced therapeutic profiles.

Positive

• Participation in the Stifel 2021 Virtual Healthcare Conference on November 17.
• On-demand Fireside Chat at the Jefferies London Healthcare Conference beginning November 18.
• Webcasts available for 30 days enhancing investor engagement.

Negative

• None.

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it will present at the following virtual healthcare conferences in November:

Stifel 2021 Virtual Healthcare Conference

• Wednesday, November 17 at 9:20 a.m. ET

Jefferies London Healthcare Conference

• Fireside Chat available on-demand beginning Thursday, November 18 at 3:00 a.m. ET

Webcasts of both the Stifel presentation and Jefferies Fireside Chat will be available via the Investors section of UroGen’s website, www.urogen.com. A replay of each webcast will be available on the Company’s website for approximately 30 days.

About UroGen Pharma Ltd.

UroGen is a biopharmaceutical company dedicated to building novel solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel^TM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005641/en/

INVESTOR CONTACT:

Lee Roth

lroth@burnsmc.com

212-213-0006

Source: UroGen Pharma Ltd.

FAQ

What conferences will UroGen Pharma (URGN) attend in November 2021?

UroGen Pharma will attend the Stifel 2021 Virtual Healthcare Conference on November 17 and the Jefferies London Healthcare Conference with an on-demand Fireside Chat available starting November 18.

Where can I access UroGen Pharma's conference webcasts?

Webcasts of UroGen Pharma's conferences will be available on the Investors section of their website for approximately 30 days.

What is the focus of UroGen Pharma's business?

UroGen Pharma focuses on developing novel solutions for treating urothelial and specialty cancers.

When will the UroGen Pharma presentation occur at the Stifel Healthcare Conference?

UroGen Pharma's presentation at the Stifel 2021 Virtual Healthcare Conference will occur on November 17 at 9:20 a.m. ET.